A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes
FGFR2b expression may serve as a predictive biomarker for therapeutic response of FGFR2b-targeted agents in sqNSCLC. The high co-expression rate of FGFR2b and PD-L1 supports the feasibility of combining FGFR2b-targeted agents with immune checkpoint inhibitors as a rational treatment strategy.
Authors
- Yayuan Fu
- Jiongyan Li
- Chunxia Ao
- Wei Sun (ORCID: https://orcid.org/0000-0003-1651-3188)
- Yang Chen (ORCID: https://orcid.org/0000-0002-6099-9448)
- Yuanjie Ge
- Haiyue Wang (ORCID: https://orcid.org/0000-0002-0350-1308)
- Xiyuan Wang (ORCID: https://orcid.org/0000-0002-2639-076X)
- Shuguang Sun (ORCID: https://orcid.org/0000-0002-0272-8340)
- Dongmei Lin
- K.N. Chi
- Renhong Tang (ORCID: https://orcid.org/0009-0005-3494-707X)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Simcere Pharmaceutical (China) (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tlcr-2025-452
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00